Application DetailsThe antibody binds specifically to α5β1 integrin, which is part of the superfamily of glycoprotein transmembrane receptors for ligands such as fibronectin, vitronectin, laminins and collagens. The α5β1 integrin receptor plays a key role in cellular processes such as inflammation, cell proliferation, angiogenesis and tumour metastasis. Comprising the variable domain of the original mouse antibody, a chimeric mouse:human IgG4 version of this antibody has been tested in vivo: In cynomolgus monkeys with laser-induced choroidal neovascularization (CNV), in rabbit models and in human volunteers. The antibody reached Phase II clinical trials with PDL Biopharma and Biogen-Idec.
TargetIntegrin alpha-5
SpecificityThe antibody binds to human α5β1 integrin with a Kd of 0.367 nM (determined by Biacore), an EC50 of 0.2 nM and an IC50 of 2.3 nM.
Target Host SpeciesHuman
Species ReactivityHuman
Antibody HostHuman
Antibody TypeRecombinant
Antibody IsotypeIgG4, kappa
Clone NameM200 (Volociximab)
ConjugateUnconjugated
Immunogen DescriptionHeterodimeric α5β1Fc fusion protein
Purity DescriptionPurified antibody, via affinity chromatography
FormatLiquid. PBS with 0.02% Proclin 300.
Concentration1 mg/mL
Storage InstructionsStore at 2-8°C for up to 1 month. For longer storage, aliquot and store at -20_C. Avoid mulitiple freeze thaw cycles.
Batch NumberPlease see item label.
Expiration DateStore at 2-8⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C for up to 12 months.
Alternative NamesFibronectin receptor; CD49 antigen-like family member E; Integrin alpha-F; VLA-5; CD49e.
Scientific BackgroundNOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. The antibody binds specifically to α5β1-integrin, which is part of the superfamily of glycoprotein transmembrane receptors for ligands such as fibronectin, vitronectin, laminins and collagens. The α5β1-integrin receptor plays a key role in cellular processes such as inflammation, cell proliferation, angiogenesis and tumour metastasis. Comprising the variable domain of the original mouse antibody, a chimeric mouse:human IgG4 version of this antibody has been tested in vivo: In cynomolgus monkeys with laser-induced choroidal neovascularization (CNV), in rabbit models and in human volunteers. The antibody reached Phase II clinical trials with PDL Biopharma and Biogen-Idec.